MCID: THY025
MIFTS: 47

Thymus Cancer

Categories: Cancer diseases, Endocrine diseases, Genetic diseases, Immune diseases, Rare diseases

Aliases & Classifications for Thymus Cancer

MalaCards integrated aliases for Thymus Cancer:

Name: Thymus Cancer 12 44 15
Thymus Neoplasms 45 74
Thymus Neoplasm 77 17
Malignant Neoplasm of Thymus 74
Neoplasm of Thymus 12
Thymoma, Familial 74
Thymic Carcinoma 74
Thymic Neoplasms 56
Thymic Neoplasm 12
Thymoma, Type C 74
Thymic Tumor 12

Classifications:



Summaries for Thymus Cancer

MedlinePlus : 44 The thymus is a small organ in your upper chest, under your breastbone. Before birth and during childhood, the thymus helps the body make a type of white blood cell. These cells help protect you from infections. Cancer of the thymus is rare. You are more likely to get it if you have other diseases such as myasthenia gravis, lupus or rheumatoid arthritis. Sometimes there are no symptoms. Other times, thymus cancer can cause A cough that doesn't go away Chest pain Trouble breathing Doctors use a physical exam, imaging tests, and a biopsy to diagnose thymus cancer. The most common treatment is surgery to remove the tumor. Other options include radiation therapy, chemotherapy, and hormone therapy. NIH: National Cancer Institute

MalaCards based summary : Thymus Cancer, also known as thymus neoplasms, is related to myasthenia gravis and small cell cancer of the lung. An important gene associated with Thymus Cancer is NKX2-1 (NK2 Homeobox 1), and among its related pathways/superpathways are Hematopoietic Stem Cell Differentiation Pathways and Lineage-specific Markers and Hematopoietic cell lineage. The drugs Prednisone and Azathioprine have been mentioned in the context of this disorder. Affiliated tissues include thymus, testes and lung, and related phenotypes are neoplasm of the thymus and dyspnea

Disease Ontology : 12 An immune system cancer located in the thymus.

Wikipedia : 77 A thymoma is a tumor originating from the epithelial cells of the thymus that may be benign or... more...

Related Diseases for Thymus Cancer

Diseases related to Thymus Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(showing 82, show less)
# Related Disease Score Top Affiliating Genes
1 myasthenia gravis 29.9 AIRE IL2 MUSK TTN
2 small cell cancer of the lung 29.8 AKT1 KIT KRT7 NKX2-1
3 thymoma 29.6 AIRE AKT1 AMPH CD5 DPYSL5 IL2
4 immunodeficiency with thymoma 11.3
5 thymic carcinoma 11.1
6 solid adenocarcinoma with mucin production 10.5 KRT7 NKX2-1
7 ovarian germ cell teratoma 10.5 KRT7 NKX2-1
8 lung acinar adenocarcinoma 10.4 KRT7 NKX2-1
9 small cell carcinoma of the bladder 10.4 KRT7 NKX2-1
10 ovarian germ cell cancer 10.4 KRT7 NKX2-1
11 dendritic cell thymoma 10.4 CD5 TTN
12 papillary adenoma 10.4 KRT7 NKX2-1
13 hemangioma of lung 10.4 AKT1 NKX2-1
14 ceruminoma 10.4 KIT KRT7
15 jejunal cancer 10.4 KIT KRT7
16 thymic epithelial tumor 10.4 CD5 KIT
17 maxillary sinus adenoid cystic carcinoma 10.4 IL2 KIT
18 thymus adenocarcinoma 10.4 CD5 KRT7
19 papillary serous adenocarcinoma 10.4 KRT7 NKX2-1
20 intratubular embryonal carcinoma 10.4 KIT KRT7
21 glandular cystitis 10.4 KRT7 LRP4
22 cribriform carcinoma 10.4 KIT KRT7
23 bladder lymphoma 10.3 CD5 KRT7
24 mixed type thymoma 10.3 CD5 KIT
25 ectopic thymus 10.3 CD5 OMG
26 adenoid basal cell carcinoma 10.3 KIT KRT7
27 malignant leydig cell tumor 10.3 KIT KRT7
28 intestinal perforation 10.3 KRT7 NKX2-1
29 ocular melanoma 10.3 IL2 KIT
30 large cell neuroendocrine carcinoma 10.3 KIT KRT7 NKX2-1
31 lymphatic system disease 10.3 CD5 IL2 TTN
32 cavernous hemangioma 10.3 KIT KRT7 NKX2-1
33 lymphoepithelioma-like thymic carcinoma 10.3 CD5 KIT
34 adenosquamous carcinoma 10.3 KIT KRT7 NKX2-1
35 small cell carcinoma 10.3 KIT KRT7 NKX2-1
36 lung adenoid cystic carcinoma 10.3 KIT NKX2-1
37 merkel cell carcinoma 10.3 KIT KRT7 NKX2-1
38 teratoma 10.3 KIT KRT7 NKX2-1
39 necrotizing sialometaplasia 10.3 CD5 KIT KRT7
40 respiratory system disease 10.3 AKT1 IL2 NKX2-1
41 rete testis adenocarcinoma 10.3 KIT NKX2-1
42 pulmonary sclerosing hemangioma 10.3 KRT7 NKX2-1
43 gastrointestinal system cancer 10.2 AKT1 KIT KRT7
44 postsynaptic congenital myasthenic syndromes 10.2 LRP4 MUSK
45 mediastinal cancer 10.2 CD5 KIT
46 gastrointestinal system disease 10.2 AKT1 IL2 KIT
47 prostate small cell carcinoma 10.2 KIT NKX2-1
48 moderately-differentiated thymic neuroendocrine carcinoma 10.2
49 poorly differentiated thymic neuroendocrine carcinoma 10.2
50 thymoma type a 10.2
51 thymoma type b 10.2
52 thymoma type ab 10.2
53 well-differentiated thymic neuroendocrine carcinoma 10.2
54 thymic neuroendocrine carcinoma 10.2
55 hidradenoma 10.1 AKT1 KRT7
56 renal cell carcinoma, nonpapillary 10.1 IL2 KIT KRT7 NKX2-1
57 leukocyte disease 10.1 AKT1 CD5 IL2 KIT
58 neuromuscular junction disease 10.0 LRP4 MUSK OMG TTN
59 fetal adenoma 10.0 CD5 NKX2-1
60 lung cancer 9.8
61 thymoma, familial 9.8
62 lymphoblastic lymphoma 9.8
63 lymphoma 9.8
64 castleman disease 9.8
65 conn's syndrome 9.8
66 germinoma 9.8
67 large cell carcinoma 9.8
68 bronchiectasis 9.8
69 myasthenia gravis congenital 9.8
70 mucoepidermoid carcinoma 9.8
71 adenoid cystic carcinoma 9.7
72 dermatomyositis 9.7
73 hemopericardium 9.7
74 pericardial effusion 9.7
75 leiomyosarcoma 9.7
76 thymus lipoma 9.7
77 agammaglobulinemia 9.7
78 benign mesothelioma 9.7
79 liposarcoma 9.7
80 histiocytoma 9.7
81 microscopic polyangiitis 9.7
82 thymus gland disease 7.5 AIRE AKT1 AMPH CD5 CNTNAP2 DPYSL5

Graphical network of the top 20 diseases related to Thymus Cancer:



Diseases related to Thymus Cancer

Symptoms & Phenotypes for Thymus Cancer

Human phenotypes related to Thymus Cancer:

33 (showing 20, show less)
# Description HPO Frequency HPO Source Accession
1 neoplasm of the thymus 33 hallmark (90%) HP:0100521
2 dyspnea 33 frequent (33%) HP:0002094
3 immunodeficiency 33 frequent (33%) HP:0002721
4 palpebral edema 33 frequent (33%) HP:0100540
5 chest pain 33 frequent (33%) HP:0100749
6 cough 33 frequent (33%) HP:0012735
7 mediastinal lymphadenopathy 33 frequent (33%) HP:0100721
8 diaphragmatic paralysis 33 frequent (33%) HP:0006597
9 dysgammaglobulinemia 33 frequent (33%) HP:0002961
10 ptosis 33 occasional (7.5%) HP:0000508
11 dysphagia 33 occasional (7.5%) HP:0002015
12 increased intracranial pressure 33 occasional (7.5%) HP:0002516
13 abnormal bleeding 33 occasional (7.5%) HP:0001892
14 autoimmunity 33 occasional (7.5%) HP:0002960
15 neuroendocrine neoplasm 33 occasional (7.5%) HP:0100634
16 headache 33 occasional (7.5%) HP:0002315
17 pericarditis 33 occasional (7.5%) HP:0001701
18 fatigable weakness 33 occasional (7.5%) HP:0003473
19 cardiac arrest 33 occasional (7.5%) HP:0001695
20 language impairment 33 occasional (7.5%) HP:0002463

MGI Mouse Phenotypes related to Thymus Cancer:

47 (showing 4, show less)
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.07 AIRE AKT1 AMPH CNTNAP2 DPYSL5 IL2
2 nervous system MP:0003631 9.9 AIRE AKT1 AMPH CD5 CNTNAP2 DPYSL5
3 no phenotypic analysis MP:0003012 9.5 AIRE CD5 IL2 KIT NKX2-1 OMG
4 respiratory system MP:0005388 9.17 AIRE AKT1 IL2 KIT LRP4 MUSK

Drugs & Therapeutics for Thymus Cancer

Drugs for Thymus Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(showing 145, show less)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2 53-03-2 5865
2
Azathioprine Approved Phase 4 446-86-6 2265
3 Immunologic Factors Phase 4,Phase 1,Phase 2,Not Applicable
4 Immunosuppressive Agents Phase 4,Phase 2,Phase 1,Not Applicable
5 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1
6 Antimetabolites Phase 4
7 glucocorticoids Phase 4,Phase 3,Phase 2
8 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 2
9 Hormones Phase 4,Phase 3,Phase 2,Phase 1
10 Antimetabolites, Antineoplastic Phase 4
11 Hormone Antagonists Phase 4,Phase 3,Phase 2
12 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2
13 Antirheumatic Agents Phase 4,Phase 1,Phase 2
14
Etoposide Approved Phase 3,Phase 2,Phase 1 33419-42-0 36462
15
Cisplatin Approved Phase 3,Phase 2,Phase 1 15663-27-1 2767 441203 84093
16
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
17
Methylprednisolone hemisuccinate Approved Phase 3,Phase 2 2921-57-5
18
Prednisolone phosphate Approved, Vet_approved Phase 3,Phase 2 302-25-0
19
Prednisolone Approved, Vet_approved Phase 3,Phase 2 50-24-8 5755
20
Methylprednisolone Approved, Vet_approved Phase 3,Phase 2 83-43-2 6741
21 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
22
Prednisolone hemisuccinate Experimental Phase 3,Phase 2 2920-86-7
23 Liver Extracts Phase 3,Phase 1,Phase 2
24 Cola Phase 3,Phase 2,Phase 1,Not Applicable
25 Etoposide phosphate Phase 3,Phase 2,Phase 1
26 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1
27 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1
28 Narcotics Phase 3
29 Adjuvants, Anesthesia Phase 3
30 Analgesics Phase 3,Phase 1,Phase 2
31 Anesthetics, Intravenous Phase 3
32 Anesthetics, General Phase 3
33 Anesthetics Phase 3
34 Analgesics, Opioid Phase 3
35 Central Nervous System Depressants Phase 3,Not Applicable
36 Peripheral Nervous System Agents Phase 3,Phase 2,Phase 1
37 Prednisolone acetate Phase 3,Phase 2
38 Methylprednisolone Acetate Phase 3,Phase 2
39
Pembrolizumab Approved Phase 2,Phase 1 1374853-91-4
40
Carboplatin Approved Phase 2,Phase 1 41575-94-4 10339178 38904 498142
41
Melphalan Approved Phase 2,Not Applicable 148-82-3 460612 4053
42
Docetaxel Approved, Investigational Phase 2 114977-28-5 148124
43
Bevacizumab Approved, Investigational Phase 2 216974-75-3
44
Pemetrexed Approved, Investigational Phase 2,Phase 1 150399-23-8, 137281-23-3 60843 446556
45
leucovorin Approved Phase 2,Phase 1 58-05-9 143 6006
46
Belinostat Approved, Investigational Phase 2,Phase 1 866323-14-0
47
Pasireotide Approved Phase 2 396091-73-9 9941444
48
Octreotide Approved, Investigational Phase 2 83150-76-9 6400441 383414
49
Paclitaxel Approved, Vet_approved Phase 2,Phase 1 33069-62-4 36314
50
rituximab Approved Phase 1, Phase 2 174722-31-7 10201696
51
Cyclophosphamide Approved, Investigational Phase 2,Phase 1 50-18-0, 6055-19-2 2907
52
Busulfan Approved, Investigational Phase 2 55-98-1 2478
53
Somatostatin Approved, Investigational Phase 2 38916-34-6, 51110-01-1 53481605
54
Sunitinib Approved, Investigational Phase 2 557795-19-4, 341031-54-7 5329102
55
Miconazole Approved, Investigational, Vet_approved Phase 2,Phase 1 22916-47-8 4189
56
Sirolimus Approved, Investigational Phase 2,Phase 1 53123-88-9 46835353 5284616 6436030
57
Everolimus Approved Phase 2,Phase 1 159351-69-6 70789204 6442177
58
Celecoxib Approved, Investigational Phase 1, Phase 2 169590-42-5 2662
59
Ramucirumab Approved, Investigational Phase 2 947687-13-0
60
Nedaplatin Approved, Investigational Phase 2 95734-82-0
61
nivolumab Approved Phase 2,Phase 1 946414-94-4
62
Amphotericin B Approved, Investigational Phase 2 1397-89-3 5280965 14956
63
Cetuximab Approved Phase 2 205923-56-4 56842117 2333
64
Doxorubicin Approved, Investigational Phase 2,Phase 1 23214-92-8 31703
65
Trametinib Approved Phase 2 871700-17-3 11707110
66
Palbociclib Approved, Investigational Phase 2 571190-30-2 5005498 11431660 5330286
67
Folic Acid Approved, Nutraceutical, Vet_approved Phase 2,Phase 1 59-30-3 6037
68
Tyrosine Approved, Investigational, Nutraceutical Phase 2,Phase 1 60-18-4 6057
69
Calcium Approved, Nutraceutical Phase 1, Phase 2 7440-70-2 271
70 Amrubicin Investigational Phase 2 110267-81-7
71
Lexatumumab Investigational Phase 2 845816-02-6
72
Lapatinib Approved March 2007, Investigational Phase 2 231277-92-2, 388082-78-8 208908 9941095
73
Doxil Approved June 1999 Phase 2,Phase 1 31703
74
Saracatinib Investigational Phase 2 379231-04-6
75
Maleic acid Experimental, Investigational Phase 2 110-17-8, 110-16-7 444972
76 Antineoplastic Agents, Immunological Phase 2,Phase 1
77 Antineoplastic Agents, Alkylating Phase 1, Phase 2,Phase 2,Not Applicable
78 Alkylating Agents Phase 1, Phase 2,Phase 2,Not Applicable
79 Antilymphocyte Serum Phase 2,Not Applicable
80 Antimitotic Agents Phase 2,Phase 1
81 Angiogenesis Modulating Agents Phase 2
82 Angiogenesis Inhibitors Phase 2
83 Protein Kinase Inhibitors Phase 2,Phase 1
84
Erlotinib Hydrochloride Phase 2 183319-69-9 176871
85 Insulin, Globin Zinc Phase 2
86 insulin Phase 2
87 Mitogens Phase 2
88 Vitamin B Complex Phase 2,Phase 1
89 Vitamin B9 Phase 2,Phase 1
90 Nucleic Acid Synthesis Inhibitors Phase 2,Phase 1
91 Folate Phase 2,Phase 1
92 Folic Acid Antagonists Phase 2,Phase 1
93 Histone Deacetylase Inhibitors Phase 2,Phase 1
94 Gastrointestinal Agents Phase 2
95 Albumin-Bound Paclitaxel Phase 2,Phase 1
96 Bendamustine Hydrochloride Phase 1, Phase 2
97 Immunoglobulins Phase 1, Phase 2,Phase 2
98 Antibodies, Monoclonal Phase 1, Phase 2,Phase 2
99 Antibodies Phase 1, Phase 2,Phase 2
100 Autonomic Agents Phase 2
101 Protective Agents Phase 2
102 Antiemetics Phase 2
103 Neuroprotective Agents Phase 2
104 Dermatologic Agents Phase 2
105 Antifungal Agents Phase 2,Phase 1
106 Anti-Infective Agents Phase 2,Phase 1
107 Calcineurin Inhibitors Phase 2
108 Cyclosporins Phase 2
109 Anti-Retroviral Agents Phase 2
110 Endothelial Growth Factors Phase 2
111 Immunoglobulin G Phase 2
112 Anti-Bacterial Agents Phase 1, Phase 2,Phase 2
113 Antibiotics, Antitubercular Phase 1, Phase 2,Phase 2
114 Cyclooxygenase Inhibitors Phase 1, Phase 2
115 Analgesics, Non-Narcotic Phase 1, Phase 2
116 Cyclooxygenase 2 Inhibitors Phase 1, Phase 2
117 Vaccines Phase 1, Phase 2
118 Anti-Inflammatory Agents, Non-Steroidal Phase 1, Phase 2
119 Calcium, Dietary Phase 1, Phase 2
120 Antiparasitic Agents Phase 2
121 Antiprotozoal Agents Phase 2
122 Liposomal amphotericin B Phase 2
123 Autoantibodies Phase 2
124
Mechlorethamine Approved, Investigational Phase 1 51-75-2 4033
125
Ifosfamide Approved Phase 1 3778-73-2 3690
126
Parathyroid hormone Approved, Investigational Phase 1 9002-64-6
127
Decitabine Approved, Investigational Phase 1 2353-33-5 451668
128
Entinostat Investigational Phase 1 209783-80-2
129
Isophosphamide mustard Phase 1 0
130 Interferon-beta Phase 1
131 interferons Phase 1
132 Imatinib Mesylate Phase 1 220127-57-1 123596
133
Cladribine Approved, Investigational Not Applicable 4291-63-8 20279
134
Histamine Approved, Investigational Not Applicable 51-45-6 774
135
Doxepin Approved, Investigational Not Applicable 1668-19-5 667468 667477
136
Promethazine Approved, Investigational Not Applicable 60-87-7 4927
137
Diphenhydramine Approved, Investigational Not Applicable 147-24-0, 58-73-1 3100
138 Hypnotics and Sedatives Not Applicable
139 Pharmaceutical Solutions Not Applicable
140 Antidepressive Agents, Tricyclic Not Applicable
141
Histamine Phosphate Not Applicable 51-74-1 65513
142 Neurotransmitter Agents Not Applicable
143 Histamine Antagonists Not Applicable
144 Antidepressive Agents Not Applicable
145 Psychotropic Drugs Not Applicable

Interventional clinical trials:

(showing 102, show less)
# Name Status NCT ID Phase Drugs
1 Study Comparing Two Tapering Strategies of Prednisone in Myasthenia Gravis Completed NCT00987116 Phase 4 Prednisone - Azathioprine
2 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
3 Thymectomy Trial in Non-Thymomatous Myasthenia Gravis Patients Receiving Prednisone Therapy Completed NCT00294658 Phase 3 prednisone alone
4 Postoperative Conformal Radiotherapy for Stage II-III B Type Thymoma Recruiting NCT02014805 Phase 3
5 Adjuvant Radiotherapy for Stage II/III Thymoma After Complete Resection Recruiting NCT02633553 Phase 3
6 Adjuvant Treatment for Incomplete Resection Thymoma or Thymic Carcinoma Recruiting NCT02633514 Phase 3 Cisplatin;Etoposide
7 A Study of Pembrolizumab for Patients With Thymic Epithelial Tumor Unknown status NCT02607631 Phase 2 Pembrolizumab
8 Neoadjuvant Chemotherapy for Locally Advanced Thymic Cancer Completed NCT01312324 Phase 2 neoadjuvant docetaxel/cisplatin
9 A Study to Test the Safety and Efficacy of Erlotinib Plus Bevacizumab to Treat Advanced Thymoma and Thymic Cancer Completed NCT00369889 Phase 2 bevacizumab;Erlotinib
10 A Phase 2 Study of Amrubicin in Relapsed or Refractory Thymic Malignancies Completed NCT01364727 Phase 2 Amrubicin
11 Multicenter Phase II Study of IMC-A12 in Patients With Thymoma and Thymic Carcinoma Who Have Been Previously Treated With Chemotherapy Completed NCT00965250 Phase 2 IMC-12
12 Phase II Study of Alimta (Pemetrexed) Treatment of Advanced Thymoma and Thymic Carcinoma Completed NCT00198133 Phase 2 Premetrexed (Alimta)
13 Belinostat (PXD101) to Treat Tumors of the Thymus at an Advanced Stage Completed NCT00589290 Phase 2 Belinostat (PDX101)
14 Heated Chemotherapy for Cancers That Have Spread to the Chest Cavity Completed NCT01163552 Phase 2
15 Preoperative Treatment of Patients With High Risk Thymoma Completed NCT00387868 Phase 2 cisplatin and etoposide
16 Efficacy of Medical Treatment With SOM230 LAR in Patients With Primary Inoperable Thymoma and/or With Local Recurrent Thymoma to Reduce Tumor Size Completed NCT02021942 Phase 2 SOM230 LAR
17 Octreotide With or Without Prednisone in Treating Patients With Metastatic or Recurrent Thymoma Completed NCT00003283 Phase 2 octreotide acetate;prednisone
18 Efficacy of Octreotide Treatment in Patients With Primary Inoperable Thymoma Completed NCT00332969 Phase 2 Octreotide
19 Carboplatin Combined With Paclitaxel in Treating Patients With Advanced Thymoma Completed NCT00010257 Phase 2 carboplatin;paclitaxel
20 Radiofrequency Ablation in Treating Patients With Refractory or Advanced Lung Cancer Completed NCT00024076 Phase 2
21 Akt Inhibitor MK2206, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Completed NCT01369849 Phase 1, Phase 2 Akt Inhibitor MK2206;Bendamustine Hydrochloride
22 Pilot Study Of Unrelated UCB Transplant for Non-Malignant Hematologic Conditions Completed NCT00003336 Phase 2 busulfan;cyclophosphamide;melphalan;methylprednisolone
23 High Dose Somatostatin Analogues in Neuroendocrine Tumors Completed NCT00990535 Phase 2 Octreotide-LAR
24 A Study of Sunitinib in Patients With Metastatic or Recurrent Thymic Carcinoma Completed NCT02623127 Phase 2 Sunitinib
25 Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer or Other Hematologic or Metabolic Diseases Completed NCT00003662 Phase 2 busulfan;cyclophosphamide;cyclosporine;melphalan;methylprednisolone
26 Effectiveness of Palifermin in Increasing CD4 Counts in Treatment-Experienced HIV Infected Adults Completed NCT00376935 Phase 2 Palifermin;Palifermin placebo
27 Erlotinib Hydrochloride and Bevacizumab in Treating Patients With Stage IV Breast Cancer Completed NCT00054132 Phase 2 Erlotinib Hydrochloride
28 Pembrolizumab and Sunitinib Malate in Treating Participants With Refractory Metastatic or Unresectable Thymic Cancer Recruiting NCT03463460 Phase 2 Sunitinib Malate
29 Carboplatin and Paclitaxel With or Without Ramucirumab in Treating Patients With Locally Advanced, Recurrent, or Metastatic Thymic Cancer That Cannot Be Removed by Surgery Recruiting NCT03694002 Phase 2 Carboplatin;Paclitaxel
30 A Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies Recruiting NCT01325441 Phase 1, Phase 2 BBI608;Paclitaxel
31 Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies Recruiting NCT01306045 Phase 2 AZD6244;MK-2206;Lapatinib;Erlotinib;Sunitinib
32 Study of Thymosin a1 During Chemoradiotherapy For Unresectable Thymoma and Thymic Carcinoma Recruiting NCT03663764 Phase 2 Thymosin a1
33 Nivolumab in Patients With Type B3 Thymoma and Thymic Carcinoma (NIVOTHYM) Recruiting NCT03134118 Phase 2 Nivolumab
34 A Pilot Study to Investigate the Safety and Clinical Activity of Avelumab (MSB0010718C) in Thymoma and Thymic Carcinoma After Progression on Platinum-Based Chemotherapy Recruiting NCT03076554 Phase 2 Avelumab
35 Ramucirumab and Carbo-Paclitaxel for Untreated Thymic Carcinoma / B3 Thymoma With Carcinoma (RELEVENT) Recruiting NCT03921671 Phase 2
36 Trial of Sunitinib in Patients With Type B3 Thymoma or Thymic Carcinoma in Second and Further Lines (Style Trial) Recruiting NCT03449173 Phase 2 Sunitinib
37 Selinexor in Patients With Advanced Thymoma and Thymic Carcinoma Recruiting NCT03466827 Phase 2 Selinexor
38 Selinexor in Patients With Advanced Thymic Epithelial Tumor Progressing After Primary Chemotherapy Recruiting NCT03193437 Phase 2 Open Label Selinexor
39 K-BASKET, TAS-117, PI3K/AKT Gene Aberration Recruiting NCT03017521 Phase 2 TAS-117
40 Continuous 24h Intravenous Infusion of Mithramycin, an Inhibitor of Cancer Stem Cell Signaling, in People With Primary Thoracic Malignancies or Carcinomas, Sarcomas or Germ Cell Neoplasms With Pleuropulmonary Metastases Recruiting NCT02859415 Phase 1, Phase 2 Mithramycin
41 CAMB/MAT2203 in Patients With Mucocutaneous Candidiasis Recruiting NCT02629419 Phase 2 Amphotericin B
42 Phase I/II Eval Safety & Prelim Activity Nivolumab Comb W/Vorolanib Pts W/Refractory Thoracic Tumors Recruiting NCT03583086 Phase 1, Phase 2 VEGFR/PDGFR Dual Kinase Inhibitor X-82
43 Sunitinib for Advanced Thymus Cancer Following Earlier Treatment Active, not recruiting NCT01621568 Phase 2 Sunitinib
44 Pembrolizumab and Epacadostat in Patients With Thymic Carcinoma Active, not recruiting NCT02364076 Phase 2 Pembrolizumab;Epacadostat
45 Study of Everolimus in Patients With Thymoma and Thymic Carcinoma Previously Treated With Chemotherapy Active, not recruiting NCT02049047 Phase 2 Everolimus
46 A Study of BKM120 (Buparlisib) in Relapsed or Refractory Thymomas Active, not recruiting NCT02220855 Phase 2 BKM120
47 Chemotherapy Plus Cetuximab Followed by Surgical Resection in Patients With Locally Advanced or Recurrent Thymoma or Thymic Carcinoma Active, not recruiting NCT01025089 Phase 2 Cetuximab, Cisplatin, Doxorubicin & Cyclophosphamide
48 Chemoradiotherapy for Limited Advanced Unresectable Thymic Epithelial Tumors Active, not recruiting NCT02636556 Phase 2
49 Akt Inhibitor MK2206 in Treating Patients With Previously Treated Colon or Rectal Cancer That is Metastatic or Locally Advanced and Cannot Be Removed by Surgery Active, not recruiting NCT01802320 Phase 2 Akt Inhibitor MK2206
50 Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Metastatic Triple-Negative Breast Cancer Active, not recruiting NCT01964924 Phase 2 Akt Inhibitor GSK2141795;Trametinib
51 A Phase II Study of Palbociclib for Recurrent or Refractory Advanced Thymic Epithelial Tumor Not yet recruiting NCT03219554 Phase 2 Palbociclib
52 neoadjuvant_thymic Epithelial Tumor Not yet recruiting NCT03858582 Phase 2 pembrolizumab
53 Adjuvant Tumor Lysate Vaccine and Iscomatrix With or Without Metronomic Oral Cyclophosphamide and Celecoxib in Patients With Malignancies Involving Lungs, Esophagus, Pleura, or Mediastinum Suspended NCT02054104 Phase 1, Phase 2 Cyclophosphamide;Celecoxib
54 Saracatinib in Treating Patients With Relapsed or Refractory Thymoma or Thymic Cancer Terminated NCT00718809 Phase 2 saracatinib
55 A Phase 1/2 Study of PXD101 (Belinostat) in Combination With Cisplatin, Doxorubicin and Cyclophosphamide in the First Line Treatment of Advanced or Recurrent Thymic, Malignancies Terminated NCT01100944 Phase 1, Phase 2 PXD101with cisplatin+doxorubicin+cyclophosphamide
56 Study Of Oral PHA-848125AC In Patients With Malignant Thymoma Previously Treated With Multiple Lines Of Chemotherapy Terminated NCT01301391 Phase 2 Milciclib Maleate
57 Paclitaxel and Cisplatin for Thymic Neoplasm Terminated NCT00818090 Phase 2 paclitaxel and cisplatin
58 Phase II Study Of Oral PHA-848125AC In Patients With Thymic Carcinoma Terminated NCT01011439 Phase 2 Milciclib Maleate
59 18F FLT Imaging Studies of Treatment Response for Lung Cancer and Thymoma Withdrawn NCT01610544 Phase 2 3'-deoxy-3'-18F fluorothymidine (FLT)
60 Intravenous Palifosfamide-tris in Combination With Etoposide and Carboplatin in Patients With Malignancies Unknown status NCT01242072 Phase 1 palifosfamide-tris
61 Intrapleural BG00001 in Treating Patients With Malignant Pleural Mesothelioma or Malignant Pleural Effusions Unknown status NCT00066404 Phase 1
62 Pilot Study of Allogeneic Tumor Cell Vaccine With Metronomic Oral Cyclophosphamide and Celecoxib in Patients Undergoing Resection of Lung and Esophageal Cancers, Thymic Neoplasms, and Malignant Pleural Mesotheliomas Completed NCT01143545 Phase 1 Celecoxib;cyclophosphamide
63 Esophageal Sparing Intensity-modulated Radiation Therapy (IMRT) for Locally-Advanced Thoracic Malignancies Completed NCT00921739 Phase 1
64 Pilot Study of Imatinib (Gleevec) as Treatment for Advanced Thymic Carcinoma Completed NCT00314873 Phase 1 Gleevec (imatinib)
65 Cixutumumab and Temsirolimus in Treating Patients With Locally Advanced or Metastatic Cancer Completed NCT00678769 Phase 1 Cixutumumab;Temsirolimus
66 MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma Completed NCT00020579 Phase 1 entinostat
67 A Open-Label, Multiple Ascending Dose Study of DS-3078a, an Oral TORC1/2 Kinase Inhibitor, in Subjects With Advanced Solid Tumors or Lymphomas Completed NCT01588678 Phase 1 DS-3078a
68 Feasibility Trial of Pembrolizumab in Unresectable Thymoma and Thymic Carcinoma Recruiting NCT03295227 Phase 1 Pembrolizumab
69 Bosutinib in Combination With Pemetrexed in Patients With Selected Metastatic Solid Tumors Recruiting NCT03023319 Phase 1 Bosutinib;Pemetrexed
70 Selinexor and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Aggressive Non-Hodgkin Lymphoma Recruiting NCT02303392 Phase 1 Selinexor;Ibrutinib
71 Study of Hypofractionated Proton Radiation Therapy in Thoracic Malignancies Active, not recruiting NCT01165658 Phase 1
72 Tumor Cell Vaccines With ISCOMATRIX Adjuvant and Celecoxib in Patients Undergoing Resection of Lung and Esophageal Cancers and Malignant Pleural Mesotheliomas Terminated NCT01258868 Phase 1 Celebrex
73 SPECTAlung: Screening Patients With Thoracic Tumors for Efficient Clinical Trial Access Unknown status NCT02214134
74 Inherited Myokymia: A Clinical and Genetic Study of a Family Unknown status NCT01250704
75 The Roles of Neutrophil Elastase in Lung Cancer Unknown status NCT01360931
76 Printed Education Materials in Patients Who Are Finishing Treatment for Stage I, Stage II, or Stage IIIA Breast Cancer, Colorectal Cancer, Prostate Cancer, or Chest Cancer Unknown status NCT00372840 Not Applicable
77 Nonmyeloablative Allogeneic Transplant Unknown status NCT01272817 Not Applicable
78 Genetic Evaluation of Families With Endocrine Cancers Completed NCT01794676
79 Cognitive Testing of Tobacco Use Measurement Items for Administration With Cancer Patients and Survivors Completed NCT02233842
80 B-Receptor Signaling in Cardiomyopathy Completed NCT01135849
81 Characteristics of Patients With Thymoma in Chulalongkorn Hospital Completed NCT01123590
82 Prospective Study of Stereotactic Body Radiation Therapy for Thymoma Inoma: Therapeutic Effect and Toxicity Assessment Completed NCT03078699 Not Applicable
83 Biology of Thymic Tumors Completed NCT00965627
84 The Role of the Thymus in Myasthenia Gravis Completed NCT01102192
85 Relationship Between Computed Tomography Manifestation and Histopathological Classification of Thymic Epithelial Tumors Completed NCT03288662 Not Applicable
86 Early Versus Late Extubation in Myasthenia Gravis Patients Completed NCT03468452
87 Thoracic OncoGeriatric Assessment (TOGA) Trials Completed NCT00591981
88 Doxepin Hydrochloride in Treating Esophageal Pain in Patients With Thoracic Cancer Receiving Radiation Therapy to the Thorax With or Without Chemotherapy Completed NCT02062632 Not Applicable Doxepin Hydrochloride
89 Radiation Therapy and Cardiac Enzymes Completed NCT00777751
90 Tissue Procurement and Natural History Study of People With Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Extrapulmonary Small Cell Cancer, Pulmonary Neuroendocrine Tumors, and Thymic Epithelial Tumors Recruiting NCT02146170
91 Integrated Cancer Repository for Cancer Research Recruiting NCT02012699
92 The Curative Effect of Extended Thymectomy Performed Through Subxiphoid-right VATS Approach With Elevation of Sternum Recruiting NCT03613272 Not Applicable
93 Confocal Laser Endomicroscopy in Pleural Malignancies Recruiting NCT03290183
94 Rapid Autopsy and Procurement of Cancer Tissue Recruiting NCT01851395
95 Variables Predicting Reintubation After Thymectomy in Patients With Myasthenia Gravis Recruiting NCT03597373
96 Immune Regulation in Patients With Common Variable Immunodeficiency and Related Syndromes Recruiting NCT00001244
97 Tissue Procurement and Natural History Study of Patients With Malignant Mesothelioma Recruiting NCT01950572
98 French National Observatory of Patients With Thymic Epithelial Tumor Recruiting NCT02724696
99 Genomic Profiling of Nodular Thyroid Disease and Thyroid Cancer Recruiting NCT03170804
100 Molecular Analysis of Thoracic Malignancies Enrolling by invitation NCT01385722
101 Preoperative Prediction of of Thymic Epithelial Tumors by Diffusion-Weighted MR Imaging Not yet recruiting NCT03212027
102 Regulation of LncRNA For Breg in Patients With Thymoma and Autoimmune Diseases Withdrawn NCT02948855

Search NIH Clinical Center for Thymus Cancer

Cochrane evidence based reviews: thymus neoplasms

Genetic Tests for Thymus Cancer

Anatomical Context for Thymus Cancer

MalaCards organs/tissues related to Thymus Cancer:

42
Thymus, Testes, Lung, Thyroid, Colon, Endothelial, Testis

The Foundational Model of Anatomy Ontology organs/tissues related to Thymus Cancer:

20
The Thymus

Publications for Thymus Cancer

Articles related to Thymus Cancer:

(showing 3, show less)
# Title Authors Year
1
Sunitinib effective for rare thymus cancer. ( 25680712 )
2015
2
Gene mutation may signal indolent thymus cancer. ( 25185203 )
2014
3
Thymus cancer epidemiology in England and Wales. ( 2372494 )
1990

Variations for Thymus Cancer

Cosmic variations for Thymus Cancer:

9 (showing 9, show less)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM44380 TP53 thymus,NS,thymic carcinoma,undifferentiated carcinoma c.376T>A p.Y126N 17:7675236-7675236 0
2 COSM14140 SMAD4 thymus,NS,thymic carcinoma,undifferentiated carcinoma c.1081C>T p.R361C 18:51065548-51065548 0
3 COSM6191487 PREX2 thymus,NS,thymic carcinoma,undifferentiated carcinoma c.107G>T p.R36L 8:67952501-67952501 0
4 COSM6191489 NOTCH2 thymus,NS,thymic carcinoma,undifferentiated carcinoma c.3359G>A p.C1120Y 1:119937445-119937445 0
5 COSM2006821 KMT2D thymus,NS,thymic carcinoma,undifferentiated carcinoma c.11824C>T p.R3942W 12:49032071-49032071 0
6 COSM133763 KIT thymus,NS,thymic carcinoma,undifferentiated carcinoma c.1657T>A p.Y553N 4:54727425-54727425 0
7 COSM6191682 KDM6A thymus,NS,thymic carcinoma,undifferentiated carcinoma c.2921C>T p.A974V 23:45078488-45078488 0
8 COSM6196604 IL7R thymus,NS,thymic carcinoma,undifferentiated carcinoma c.537+1G>T p.? 5:35871214-35871214 0
9 COSM6191486 FAT1 thymus,NS,thymic carcinoma,undifferentiated carcinoma c.12706A>G p.K4236E 4:186596834-186596834 0

Expression for Thymus Cancer

Search GEO for disease gene expression data for Thymus Cancer.

Pathways for Thymus Cancer

Pathways related to Thymus Cancer according to GeneCards Suite gene sharing:

(showing 2, show less)
# Super pathways Score Top Affiliating Genes
1 11.2 CD5 IL2 KIT
2 10.79 CD1E CD5 KIT

GO Terms for Thymus Cancer

Biological processes related to Thymus Cancer according to GeneCards Suite gene sharing:

(showing 7, show less)
# Name GO ID Score Top Affiliating Genes
1 phosphorylation GO:0016310 9.8 AKT1 KIT MUSK STK16 TTN
2 protein phosphorylation GO:0006468 9.72 AKT1 KIT MUSK STK16 TTN
3 positive regulation of gene expression GO:0010628 9.55 AKT1 KIT MUSK NKX2-1 TTN
4 negative regulation of axonogenesis GO:0050771 9.37 LRP4 OMG
5 skeletal muscle acetylcholine-gated channel clustering GO:0071340 9.26 LRP4 MUSK
6 peptidyl-tyrosine phosphorylation GO:0018108 9.26 KIT MUSK STK16 TTN
7 protein autophosphorylation GO:0046777 8.92 AKT1 KIT MUSK STK16

Molecular functions related to Thymus Cancer according to GeneCards Suite gene sharing:

(showing 2, show less)
# Name GO ID Score Top Affiliating Genes
1 kinase activity GO:0016301 9.35 AKT1 KIT MUSK STK16 TTN
2 protein kinase activity GO:0004672 9.02 AKT1 KIT MUSK STK16 TTN

Sources for Thymus Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....